NewLink Genetics’ Pancreatic Cancer Treatment Flops in Phase 3 Study

NewLink Genetics Corp.’s investigational drug algenpantucel-L missed the mark in a Phase 3 trial testing its use in resected pancreatic cancer, leading the company to pursue other options.

The candidate failed to meet the primary endpoint of overall survival, with no statistically significant difference between the treatment and standard care versus standard care alone.

The company says it will focus instead on its IDO checkpoint inhibitor platform — indoximod and GDC — in targeting solid tumors and metastatic, breast, prostate and pancreatic cancers, advanced melanoma and glioblastoma.